Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Resistance
Research from T. Ueda et al broadens understanding of drug resistance
June 15th, 2009
According to recent research from Osaka, Japan, "Glucagon-like peptide 1 (7-36) amide (GLP-1) has been attracting considerable attention as a therapeutic agent for the treatment of type 2 diabetes. In this study, we applied a glycoengineering strategy to GLP-1 to improve its proteolytic stability and in vivo blood glucose-lowering activity." "Glycosylated analogues with N-acetylglucosamine (GIcNAc), N-acetyllactosamine (LacNAc), and alpha 2,6-sialyl N-acetyllactosamine (sialyl LacNAc) were prepared by chemoenzymatic approaches. We assessed the receptor binding affinity and CAMP production activity in vitro, the proteolytic resistance against dipeptidyl peptidase-IV...
Source: Diabetes Week (2009-06-15)
|
